Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271725 | 0.84 | GPR119 (0.53) | GPR119 | |
| SCHEMBL19030310 | 0.82 | IKBKB (0.48) | IKBKBCHUKGPR119EPHX2NAMPT | |
| SCHEMBL25584602 | 0.81 | IKBKB (0.40) | IKBKBCHUKGPR119SSTR4 | |
| SCHEMBL9903544 | 0.80 | EPHX2 (0.62) | EPHX2KMT2ARBP4 | |
| SCHEMBL25584605 | 0.78 | MKNK1 (0.41) | IKBKBCHUKSSTR4 | |
| SCHEMBL15691866 | 0.77 | GPR119 (0.43) | IKBKBCHUKGPR119EPHX2 | |
| SCHEMBL639198 | 0.77 | EPHX2 (0.60) | IKBKBCHUKEPHX2NAMPTALDH1A1 | |
| SCHEMBL25246190 | 0.76 | IKBKB (0.43) | IKBKBCHUKNAMPT | |
| SCHEMBL31302342 | 0.76 | IKBKB (0.43) | IKBKBCHUKNAMPT | |
| SCHEMBL14157549 | 0.76 | GPR119 (0.58) | IKBKBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2018-12-11 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2015-11-12 | — | — | US | disclosed |
| US-9023872-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130137671-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC. | 2013-05-30 | — | — | US | disclosed |
| US-8207198-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1841758-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-7557131-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137671-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | IKBKB 1521/4885CHUK 761/4885GPR119 111/4885 |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | IKBKB 1521/4885CHUK 761/4885GPR119 111/4885 |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | IKBKB 1521/4885CHUK 761/4885GPR119 111/4885 |
| US-20060160786-A1 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | IKBKB 1521/4885CHUK 761/4885GPR119 111/4885 |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | IKBKB 1521/4885CHUK 761/4885GPR119 111/4885 |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | IKBKB 1521/4885CHUK 761/4885GPR119 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.